Marina Chiara Garassino to Colorectal Neoplasms
This is a "connection" page, showing publications Marina Chiara Garassino has written about Colorectal Neoplasms.
Connection Strength
0.995
-
Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab? J Clin Oncol. 2008 May 20; 26(15):2600; author reply 2601-2.
Score: 0.186
-
Development and clinical indications of cetuximab. Int J Biol Markers. 2007 Jan-Mar; 22(1 Suppl 4):S40-6.
Score: 0.169
-
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discov. 2022 01; 12(1):90-107.
Score: 0.119
-
[Locoregional therapy in hepatic metastases of colorectal cancer]. Tumori. 2001 Jan-Feb; 87(1 Suppl 1):S70-2.
Score: 0.112
-
Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. Int J Colorectal Dis. 2015 Mar; 30(3):429-30.
Score: 0.072
-
The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. Cancer Treat Rev. 2014 May; 40(4):485-94.
Score: 0.067
-
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol. 2012 Oct; 23(10):2771-2772.
Score: 0.062
-
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis. 2011 Apr; 43(4):286-94.
Score: 0.056
-
Cetuximab for metastatic colorectal cancer. N Engl J Med. 2009 Jul 02; 361(1):95; author reply 96-7.
Score: 0.050
-
Cetuximab for colorectal cancer. N Engl J Med. 2008 Mar 13; 358(11):1196; author reply 1196-7.
Score: 0.046
-
An oxaliplatin + 5-fluorouracil bolus + folinic acid (BFOL) regimen as first-line treatment in metastatic colorectal cancer patients. Tumori. 2007 Nov-Dec; 93(6):557-61.
Score: 0.045
-
Predicting response of molecular targeted therapies: a still possible challenge? Ann Oncol. 2008 May; 19(5):829-30.
Score: 0.011